|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsor: | Hadassah Medical Organization |
|---|---|
| Information provided by: | Hadassah Medical Organization |
| ClinicalTrials.gov Identifier: | NCT00801372 |
Purpose
Induced pluripotent stem cells potentially may be useful in the future as an unlimited source of cells for transplantation.
The major goal of the project is to develop human iPS cells from existing lines of fibroblasts that were originally donated as clinical grade feeders for the development of clinical grade hESCs. The clinical grade feeders were developed from aborted fetuses, foreskin and umbilical cord.
| Condition |
|---|
|
Pregnant, Healthy Females Healthy Male Newborns |
| Study Type: | Observational |
| Study Design: | Case Control, Prospective |
| Official Title: | Use of Existing Fibroblast Cells to Convert to Induced Pluripotent Stem Cells |
| Estimated Enrollment: | 1 |
| Study Start Date: | November 2008 |
| Estimated Study Completion Date: | December 2011 |
| Groups/Cohorts |
|---|
|
Pre-existing Fibroblast MCB
Pre-existing fibroblast donors for hESC derivation project
|
The potential to reprogram somatic cells into an embryonic state raises multiple basic research questions related both to the process of reprogramming and the properties of iPS cells. We will use various approaches to study the molecular mechanisms and processes that occur during reprogramming. We will use various experimental systems to characterize and study the properties of the iPS cells, their biology, developmental potential, capability to give rise to functional differentiated progeny etc.
The clinical grade donated feeders used in this project were developed under GMP conditions using animal-free reagents. For potential future clinical applications, the iPS cells will be developed under GMP conditions, using reagents and methods that will be acceptable for clinical applications.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
pregnant, healthy females older than 18 who signed an informed consent for the termination of the pregnancy.
pregnant healthy couples older than 18 who signed an informed consent for a c-section.
healthy male newborns, undergoing surgical circumcision who's parents older than 18 signed an informed consent.
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations More Information
| Responsible Party: | Hadassah Medical Organization ( Prof. Benjamin Reubinoff ) |
| Study ID Numbers: | HMO-0522-08 |
| Study First Received: | December 2, 2008 |
| Last Updated: | November 18, 2009 |
| ClinicalTrials.gov Identifier: | NCT00801372 History of Changes |
| Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
|
pregnant, healthy females older than 18 who signed an informed consent for the termination of the pregnancy. pregnant healthy couples older than 18 who signed an informed consent for a c-section. healthy male newborns, undergoing surgical circumcision who's parents older than 18 signed an informed consent. |
